Regen BioPharma Inc (RGBP)

[bme]

A $25 billion biotech's stock is popping on its promising cancer data.
The drugmaker, which has one approved product to treat bone-marrow disorders, is developing a cancer immunotherapy called an IDO inhibitor. The goal with these treatments is to harness the body's immune system to attack cancer. The hope is that these IDO-inhibitor drugs will be used alongside PD-1 inhibitors (of which numerous have already been approved) to help more people respond to cancer treatments than if they used the PD-1 inhibitors alone. Incyte's data that came out Wednesday made it seem as if that might be the case, at least in some forms of cancer.
https://www.yahoo.com/news/m/06ca977d-4e05-39f3-ab6c-7ef070e82131/ss_a-%2425-billion-biotech%27s-stock.html
RGBP